bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: D N O S A J J M A M F J
2013: D

 
  Other news for:
Hematologic Diseases
Genetics
Technology, Medical
Tissue Donors
 Resources from HONselect
FDA OKs Test to Improve Blood Donor-Recipient Matching
New method uses genetics and computer technology to determine most compatible red blood cells

By Robert Preidt

THURSDAY, May 22, 2014 (HealthDay News) -- The first gene-based test to help determine red blood cell compatibility between a blood donor and a recipient has been approved by the U.S. Food and Drug Administration.

The four major blood groups -- A, B, AB or O -- are determined by the presence or absence of two antigens (A and B) on the surface of red blood cells, according to the American Red Cross. In addition, a third antigen -- the Rh factor -- can be either present (positive) or absent (negative). An antigen is a substance that prompts the immune system to produce antibodies against it.

Red blood cells also have minor blood group antigens (non-ABO antigens). Some people develop antibodies to non-ABO antigens after receiving a blood transfusion or following pregnancy. People who receive repeated blood transfusions (such as those with sickle cell disease) are especially likely to develop antibodies to non-ABO antigens, the FDA explained in a news release.

These antibodies can result in the destruction of a patient's red blood cells if they later receive blood cells with the same non-ABO antigens, the FDA said.

Now, the Immucor PreciseType Human Erythrocyte Antigen (HEA) Molecular BeadChip Test can be used to identify non-ABO red blood cell types, according to the news release.

The test is designed to help prevent the development of antibodies to non-ABO antigens by giving patients blood that is better matched to their non-ABO antigens. Experts say that the destruction of red blood cells can be avoided if patients with known non-ABO antigens receive blood that does not contain the same non-ABO antigens.

Current blood testing sometimes fails to detect certain non-ABO antigens. The new test offers a way to detect non-ABO antigens that may otherwise be missed, according to the FDA.

The new test "may enhance patient care in certain situations," Dr. Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research, said in an FDA news release.

The new test is made by BioArray Solutions Ltd., of Warren, N.J.

More information

The U.S. National Heart, Lung, and Blood Institute has more about blood transfusion.

SOURCE: U.S. Food and Drug Administration, news release, May 21, 2014

Copyright © 2014 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=688110

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Blood
Cells
Blood Cells
Erythrocytes
Blood Transfusion
Tissue Donors
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact